Lymph node dissection for stage III melanoma

Maggie L. Diller; Benjamin M. Martin; Keith A. Delman

doi:10.1016/j.soc.2014.12.005

Lymph node dissection for stage III melanoma

Maggie L. Diller, Benjamin M. Martin, Keith A. Delman

Surgery

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations. Surgical morbidity after lymphadenectomy can be substantial, creating opportunities for improvement via minimally invasive techniques or refined patient selection.

Original language	English (US)
Pages (from-to)	261-277
Number of pages	17
Journal	Surgical Oncology Clinics of North America
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/j.soc.2014.12.005
State	Published - Apr 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Inc.

Keywords

Locoregional spread
Lymphadenectomy
Stage III melanoma
Videoscopic inguinal lymphadenectomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.soc.2014.12.005

Find It

Find It at U of M Libraries

Cite this

@article{931e8b58273d4ac4a0f4a903b907e14e,

title = "Lymph node dissection for stage III melanoma",

abstract = "Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations. Surgical morbidity after lymphadenectomy can be substantial, creating opportunities for improvement via minimally invasive techniques or refined patient selection.",

keywords = "Locoregional spread, Lymphadenectomy, Stage III melanoma, Videoscopic inguinal lymphadenectomy",

author = "Diller, {Maggie L.} and Martin, {Benjamin M.} and Delman, {Keith A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.soc.2014.12.005",

language = "English (US)",

volume = "24",

pages = "261--277",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Lymph node dissection for stage III melanoma

AU - Diller, Maggie L.

AU - Martin, Benjamin M.

AU - Delman, Keith A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations. Surgical morbidity after lymphadenectomy can be substantial, creating opportunities for improvement via minimally invasive techniques or refined patient selection.

AB - Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations. Surgical morbidity after lymphadenectomy can be substantial, creating opportunities for improvement via minimally invasive techniques or refined patient selection.

KW - Locoregional spread

KW - Lymphadenectomy

KW - Stage III melanoma

KW - Videoscopic inguinal lymphadenectomy

UR - http://www.scopus.com/inward/record.url?scp=84925933705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925933705&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2014.12.005

DO - 10.1016/j.soc.2014.12.005

M3 - Review article

C2 - 25769711

AN - SCOPUS:84925933705

SN - 1055-3207

VL - 24

SP - 261

EP - 277

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 2

ER -

Lymph node dissection for stage III melanoma

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this